HeartBeam Announces Public Offering to Fund Cardiac Technology Commercialization and AI Development
HeartBeam Inc. is launching a public offering to finance the commercialization of its FDA-cleared 12-lead ECG system and advance AI initiatives for cardiac care.
HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it is commencing an underwritten public offering of shares of its common stock or common stock equivalents. The company said it intends to use net proceeds from the offering to advance commercialization of its FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection initiatives, enhance its AI capabilities and support working capital and general corporate purposes.
The offering represents a strategic move to accelerate the company's mission of transforming cardiac care through portable technology. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.
Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. More details on the intended use of its technology are available at https://www.heartbeam.com/indications.
The public offering's success could significantly impact how cardiac conditions are detected and monitored globally. By enabling ECG collection outside traditional medical facilities, HeartBeam's technology addresses critical gaps in cardiac care accessibility and early intervention. The company holds over 20 issued patents related to technology enablement, providing a strong foundation for its commercialization efforts.
Titan Partners, a division of American Capital Partners, is acting as sole bookrunner for the offering. The final size and terms of the offering are subject to market conditions, with all securities to be offered by the company. This financial move comes as HeartBeam seeks to capitalize on its FDA clearances and expand its market presence in the competitive medical technology sector.
The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. The company's technology represents a significant advancement in making sophisticated cardiac monitoring available beyond hospital settings, potentially reducing healthcare costs and improving patient outcomes through earlier detection and intervention.